pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

388 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT776Endpoints579BioPharma Dive223onclive165Fierce Biotech54BioSpace52raps22
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6Hematology
  • <![CDATA[AVB-001 Encapsulated IL-2 Cell Therapy Shows Safety and Immune Activity in Platinum-Resistant HGSOC]]>
    <![CDATA[AVB-001 was tolerable and activated CD8+ and CD4+ T cells without regulatory T-cell expansion in platinum-resistant high-grade serous ovarian carcinoma.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Hunter on Luspatercept and Other Treatment Options for Anemia in Myelofibrosis]]>
    <![CDATA[Anthony M. Hunter, MD, discusses treatment decision-making for the management of anemia in myelofibrosis.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Jones on the Protective Benefit and Tolerability of GLP-1 Agonists vs Aspirin for CRC Prevention]]>
    <![CDATA[Colton Jones, MD, shares data from a retrospective analysis of GLP-1 receptor agonists vs aspirin for the primary prevention of colorectal cancer.]]>
← prev
page 8 of 16
next →
6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
onclive · 2mo ago
↗ source
  • <![CDATA[IO in NMIBC, Radioligand Therapy in mHSPC Highlight Key Presentations to Watch at AUA 2026 ]]>
    <![CDATA[Ahead of the 2026 AUA Annual Meeting, GU cancer experts highlighted the abstracts that they are anticipating the most.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Ibrutinib Monotherapy Yields Decade-Long Durable Efficacy in Across CLL Subtypes]]>
    <![CDATA[Ibrutinib monotherapy produced durable efficacy over 10 years in patients with or without TP53-mutated chronic lymphocytic leukemia.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Imaging Clues That Raise Suspicion for Diffuse Midline Glioma]]>
    <![CDATA[n this episode, Dr. Chong sets up the clinical reality that patients usually present with imaging before tissue and asks Dr. Shonka how MRI findings should shape suspicion for DMG. ]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Two Diseases That Share a Name — Defining Glioblastoma and Diffuse Midline Glioma Under the 2021 WHO Classification]]>
    <![CDATA[In this opening episode, Dr. Shonka and Dr. Chong frame the conversation around two diseases that share the name glioma but differ fundamentally in biology, demographics, and treatment.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Evolving Strategies for Myelofibrosis-Associated Anemia Highlight Persistent Gaps in Biomarker Guidance]]>
    <![CDATA[Aaron Gerds, MD, MS, and Anthony M. Hunter, MD, break down the challenges of anemia management in myelofibrosis and potential treatment avenues.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Perioperative Durvalumab Plus Neoadjuvant EV Displays EFS, OS Benefits vs SOC in MIBC]]>
    <![CDATA[Perioperative durvalumab plus EV showed positive topline efficacy findings in MIBC.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Rintatolimod Plus Pembrolizumab and Cisplatin Displays 50% ORR in Recurrent Ovarian Cancer]]>
    <![CDATA[The addition of rintatolimod to pembrolizumab and cisplatin demonstrated robust albeit preliminary antitumor activity in patients with recurrent ovarian cancer. ]]>
    onclive · 2mo ago↗ source
  • Create Medicines raises $122M to bolster in vivo CAR-T therapies
    <figure><div><img src="https://imgproxy.divecdn.com/1TNhYQTUI7yObB637nFZIAJqv_C_vHe6B8CqUtpkWHg/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMTQwMTQ3MDc2LmpwZ…
    BioPharma Dive · 2mo ago↗ source
  • <![CDATA[Dana-Farber Study Finds Stage IV Breast Cancer Increasing in Incidence and Proportion Over the Last Decade]]>
    <![CDATA[A Dana-Farber study showed cases of stage IV breast cancer are increasing in incidence and as a proportion of all breast cancer diagnoses. ]]>
    onclive · 2mo ago↗ source
  • Biogen pushing tau drug forward despite Alzheimer’s study failure
    <figure><div><img src="https://imgproxy.divecdn.com/Uto2VRn61o7u_sFbw6zPAlwZMdRxZOBYNj0bVh4-oRI/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9CaW9nZW5fUGhvdG9fMy5KUEc=.webp"/><…
    BioPharma Dive · 2mo ago↗ source
  • <![CDATA[REVELUTION-2 Trial Is Evaluating Cardiovascular Risk With Relugolix Plus Abiraterone Acetate in High-Risk Prostate Cancer]]>
    <![CDATA[Sagar A. Patel, MD, discusses the REVELUTION-2 trial evaluating cardiovascular safety with hormone therapy in prostate cancer.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Clinical Implementation and Surveillance Strategies]]>
    <![CDATA[]]>
    onclive · 2mo ago↗ source
  • With new data, Regenxbio to seek FDA approval of Duchenne gene therapy
    <figure><div><img src="https://imgproxy.divecdn.com/URuUijrNJW-L44_y5Wz5m0hLgGi4R29BBYR8egTUghQ/g:nowe:327:163/c:3508:1982/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWd…
    BioPharma Dive · 2mo ago↗ source
  • <![CDATA[Case Introduction and ctDNA as Emerging Risk Factor]]>
    <![CDATA[]]>
    onclive · 2mo ago↗ source
  • <![CDATA[ASCO 2026: All Eyes Are on Daraxonrasib and a Wave of Novel Targeted Therapies in GI Malignancies]]>
    <![CDATA[Ahead of the 2026 ASCO Annual Meeting, experts in GI malignancies share the most anticipated research being presented during the meeting.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[MET Alterations in NSCLC: Amplification, Mutations, and Therapeutic Strategies]]>
    <![CDATA[Decode MET-altered lung cancer: amplification, exon 14 skipping and co-mutations, plus evolving targeted therapies and tumor board insights.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Planned HERIZON-GEA-01 Analyses and the Doublet-vs-Triplet Question]]>
    <![CDATA[New HER2+ gastric cancer data show triplet immunotherapy boosts survival and durable responses, hinting immune activation beyond HER2 targets.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[HERIZON-GEA-01 Efficacy Results and Interpretation of Duration of Response]]>
    <![CDATA[HORIZON-GA01 shows zenidatamab regimens significantly improve survival in HER2-positive gastric cancer, while PD-L1 testing differences raise key questions for treatment choice.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Five-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase 3 trial (CT029)]]>
    <![CDATA[Five-year Phase III data show tebentafusp doubles survival in metastatic uveal melanoma, with ctDNA response predicting benefit beyond imaging and progression.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Emerging Biomarkers in NSCLC: TROP2 Scoring and MTAP Loss]]>
    <![CDATA[How Trop2 and MTAP-loss reshape NSCLC therapy, with AI pathology refining ADC response prediction and guiding trial referrals.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Evolving Oral SERD Research Seeks to Redefine Treatment Strategies in Hormone Receptor+ Breast Cancer]]>
    <![CDATA[Breast cancer experts discuss the nuances of ESR1 mutations and oral SERD use in hormone receptor–positive breast cancer.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Immunotherapy Advances in Upfront SCAC Expose Need for Better Second-Line Strategies]]>
    <![CDATA[Aparna R. Parikh, MD, emphasizes the feasibility of immunotherapy trials in SCAC and the need for better treatment options in the second line and beyond. ]]>
    onclive · 2mo ago↗ source